Sarepta Therapeutics (SRPT)
Health Care · Rare genetic disease therapeutics · NASDAQ
A biopharmaceutical leader in genetic medicine, specializing in innovative RNA-targeted therapies and gene treatments for Duchenne muscular dystrophy and rare genetic disorders.
What Sarepta Therapeutics does
Sarepta Therapeutics develops and commercializes therapies for rare genetic muscular dystrophies and other serious genetic diseases. The company markets several antisense oligonucleotide therapies for Duchenne muscular dystrophy (DMD) and has an approved gene therapy product for early-onset Duchenne muscular dystrophy. Sarepta generates revenue from product sales and strategic collaborations while investing heavily in research and development of pipeline candidates targeting monogenic rare diseases.
Themes: rare diseases, gene therapy, RNA therapeutics, Duchenne muscular dystrophy (DMD), genetic medicine
Fundamentals
- Price$18.79 as of 2026-08-21 close
- Market cap$2.0B as of 2026-08-21
- 1-year return-6.3% 2025-08-21 close $20.06 → 2026-08-21 close $18.79
- P/En/a negative earnings
- Net margin-6.9% as of 2026-08-24
- Gross margin+67.5% as of 2026-08-24
- ROE-10.0% as of 2026-08-24
- Debt / equity0.55 as of 2026-08-24
- Revenue growth (YoY)-20.4% as of 2026-08-24
- Revenue CAGR (3y)+33.1% SEC XBRL
- Beta0.34 as of 2026-08-24
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How SRPT compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 10% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
SRPT is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
51.9 #663 of 1,704 scored · #128 of 240 in Health Care
Volume and participation 86th: trading volume is about normal versus its 30-day average; trend 65th: the price is 11% above the average price paid over the period covered, so the typical buyer over that stretch is showing a gain; weakest is setup 41st: day-to-day price swings are about average versus its own recent 6-month history. Its score is docked 10 points for overextended (RSI above 75 or stochastic above 90).
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How Sarepta Therapeutics looks technically
Sarepta Therapeutics (SRPT) is trading 1.8% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 50 trading days ago — a "death cross", a bearish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 22 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 59, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 3 trading days ago. It is 25.8% below its highest point of the past year.
Trend
7
| Distance from the 200-day | it is trading 1.8% below its 200-day average, the long-term trend line — a long-term downtrend | -1.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $17.29 | $17.29 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $19.14 | $19.14 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 18 calendar days ago — the swings before that are what the structure reading is measured on | 18 sessions |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 50 trading days ago — a "death cross", a bearish long-term signal | 50 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 22 (a reading of 25+ marks a strong trend) | 21.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 59, neither overbought (above 70) nor oversold (below 30) | 59.3 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($15.64 to $20.19) — its "stochastic" reading is 69 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 69.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 12 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $25.32 | $25.32 |
|---|---|---|
| From the 52-week high | it is 25.8% below its 52-week high (its highest price of the past year) | -25.8% |
| Above the 52-week low | it is 28.0% above its 52-week low (its lowest price of the past year) | +28.0% |
| Below the 52-week high | it is 25.8% below its highest point of the past year | 25.8% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day low about 16 trading days ago | 16 sessions |
| All-time high | its highest closing price on record is $181.83 (set on 2020-12-22) | $181.83 |
| Given back of the 52-week move | over the past year its closes ranged ($14.86 to $24.45), and it has recovered roughly a third of its fall from last year’s high — 41% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $20.79 to $21.09. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 41.0% |
| From the all-time high | it is 89.7% below its all-time high | -89.7% |
| Nearest price level | it is trading 2.9% above a support level at $18.25 — a price it turned at five times since 2025-06-16, most recently on 2026-06-22. Since 2024-08-21 it has 4 such levels below the current price and 12 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -2.9% |
| All-time low | its lowest closing price on record is $2.59 (set on 2012-05-18) | $2.59 |
| Above the all-time low | it is 624.2% above its all-time low | +624.2% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 65th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.9469 between its high and its low — about 5.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.9469 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $14.35 and $19.97 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $14.35 – $17.16 – $19.97 |
| Typical daily range (% of price) | its price moves about 5.0% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.0% |
| Stretch from the 200-day average | it is trading 0.4 daily ranges below its 200-day average price (1.8% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.4 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.56× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has improved toward "buy" since the prior reading | 0.07 toward buy |
Candlestick patterns
2
| Since a doji | 6 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 6 sessions ago |
|---|---|---|
| Since a bullish engulfing | 9 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 9 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.9% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.9% |
|---|---|---|
| Open gap | it gapped 4.0% above the previous close 2 sessions ago and has not traded back through the level it left behind at 18.02 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +4.0% |
| Gap filled | a 5.0% gap up opened on 2026-07-27 has been "filled" 18 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 18 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -4.76% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 13.6 percentage points (the stock gained 15.9% while the market gained 2.3%) | +13.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 7.7 percentage points (the stock gained 10.8% while the market gained 3.1%) | +7.7% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 11.5 percentage points (the stock lost 0.5% while the market gained 11.1%) | -11.5% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 26.8 percentage points (the stock lost 6.3% while the market gained 20.5%) | -26.8% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a fresh 20-day high, MACD momentum is positive — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is moderate, spanning 3.8% of the share price. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 1% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $18.99 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | -1.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 5% above the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $17.94 — a volume-weighted average of daily closes over 13 sessions, not a true tick-by-tick VWAP. | +4.8% |
Price levels it has turned at before
SRPT last closed at $18.79 on 2026-08-21. Since 2024-08-21 it has turned at 4 prices below its last close and 12 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $18.25 | Support | 2.9% below the last close | turned there five times · 2025-06-16 to 2026-06-22 |
| $19.39 | Resistance | 3.2% above the last close | turned there four times · 2025-07-30 to 2026-02-25 |
| $20.13 | Resistance | 7.1% above the last close | turned there three times · 2025-11-14 to 2026-01-20 |
| $16.88 | Support | 10.2% below the last close | turned there three times · 2025-07-01 to 2026-02-05 |
| $20.90 | Resistance | 11.2% above the last close | turned there twice · 2025-10-14 to 2026-07-09 |
| $15.87 | Support | 15.6% below the last close | turned there twice · 2025-11-19 to 2026-06-26 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · Broke out to a new 20-day high · lagging the market · Trading at this year’s average price paid (anchored VWAP) · Trading inside the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingHold (2.67 mean, 1=Strong Buy…5=Strong Sell) — 23 analysts
- Mean price target$22.09 range $5.00 – $38.00; median $20.00
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for SRPT
- Consensus EPS estimate$0.3897 next reporting period, as of 2026-08-24
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant dependence on a limited number of products and therapeutic areas, particularly Duchenne muscular dystrophy.","Risks associated with intellectual property litigation and the ability to maintain patent protection or market exclusivity for key therapies.","Uncertainty of successful clinical development and regulatory approval for early-stage pipeline candidates."]
What changed in the latest 10-Q
AI-assisted comparison of SRPT's 10-Q filed 2026-05-06 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Reworded:
- Annual Report reference year changed from 'December 31, 2024' (filed 2025-11-06) to 'December 31, 2025' (filed 2026-05-06)
- Formatting corrected: 'Item 2. Management's Discussio n and Analysis' (filed 2025-11-06) changed to 'Item 2. Management's Discussion and Analysis' (filed 2026-05-06)
- Notes:
- Text appears truncated in both versions at 'Part II-', preventing full comparison of complete section content
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
- Last 180 days0 buys · 1 sell ($123208) — 1 selling insider
Most recent open-market transaction: 2026-03-12. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about SRPT's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 1 matched disclosure for SRPT from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
6 institutional 13F filers reported holding SRPT as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 25,463,960
- Reported value $554,095,762
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
SRPT had 27,566,969 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
SRPT had 26.1% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 8.77 days to cover at the same settlement.
- Reported short interest (shares) 27,566,969
- Short interest (% of shares outstanding) 26.1%
- Prior settlement (shares) 28,489,470
- Reported change -3.24%
- Days to cover (reported) 8.77
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Biogen (BIIB)
- PTC Therapeutics (PTCT)
- Roche (RHHBY)
- Solid Biosciences (SLDB)
- Wave Life Sciences (WVE)
- Pfizer (PFE)
- Sanofi (SNY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare SRPT vs…
Sarepta Therapeutics is found in…
SRPT ranks in…
Frequently asked questions
What does Sarepta Therapeutics (SRPT) do?
Sarepta Therapeutics develops and commercializes therapies for rare genetic muscular dystrophies and other serious genetic diseases. The company markets several antisense oligonucleotide therapies for Duchenne muscular dystrophy (DMD) and has an approved gene therapy product for early-onset Duchenne muscular dystrophy.
What sector is Sarepta Therapeutics (SRPT) in?
Sarepta Therapeutics (SRPT) is classified in the Health Care sector. Its industry is Rare genetic disease therapeutics. It trades on NASDAQ.
Who are Sarepta Therapeutics's (SRPT) competitors?
Notable peers of Sarepta Therapeutics (SRPT) include Biogen, PTC Therapeutics, Roche, Solid Biosciences and Wave Life Sciences. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in SRPT?
Yes — we hold 1 matched STOCK Act disclosure for SRPT from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Sarepta Therapeutics (SRPT) overbought or oversold right now?
Sarepta Therapeutics (SRPT) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 59, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on SRPT come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.